Can proteomics-based approaches further help COVID-19 prevention and therapy?
作者信息
Kumar Vijay
机构信息
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA.
出版信息
Expert Rev Proteomics. 2021 Apr;18(4):241-245. doi: 10.1080/14789450.2021.1924684. Epub 2021 May 16.
Abstract
摘要
相似文献
1
Can proteomics-based approaches further help COVID-19 prevention and therapy?基于蛋白质组学的方法能否进一步助力新冠病毒疾病的预防与治疗？
Expert Rev Proteomics. 2021 Apr;18(4):241-245. doi: 10.1080/14789450.2021.1924684. Epub 2021 May 16.
2
Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.通过筛析法了解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的多样性如何影响疫苗保护效果。
PLoS Pathog. 2021 Mar 25;17(3):e1009406. doi: 10.1371/journal.ppat.1009406. eCollection 2021 Mar.
3
Vaccine against SARS-CoV-2 in previously infected health care workers.曾感染过新冠病毒的医护人员接种新冠病毒疫苗。
EBioMedicine. 2021 Sep;71:103556. doi: 10.1016/j.ebiom.2021.103556. Epub 2021 Aug 26.
4
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines.快速传播的新冠病毒变异株：对新冠疫苗的挑战及新设计策略
Signal Transduct Target Ther. 2021 Jun 9;6(1):226. doi: 10.1038/s41392-021-00644-x.
5
Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的进化：对谱系和疫苗有效性的预测
Travel Med Infect Dis. 2021 Mar-Apr;40:101983. doi: 10.1016/j.tmaid.2021.101983. Epub 2021 Feb 4.
6
Being fair to participants in placebo-controlled COVID-19 vaccine trials.公平对待参与新冠病毒疫苗安慰剂对照试验的受试者。
Nat Med. 2021 Jun;27(6):938. doi: 10.1038/s41591-021-01338-1.
7
Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed.实现全球公平分配 COVID-19 疫苗：需要加强国际伙伴关系，增强宣传和团结。
PLoS Med. 2021 Sep 13;18(9):e1003772. doi: 10.1371/journal.pmed.1003772. eCollection 2021 Sep.
8
The challenge of emerging SARS-CoV-2 mutants to vaccine development.新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）突变体对疫苗研发的挑战。
J Genet Genomics. 2021 Feb 20;48(2):102-106. doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20.
9
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗（BNT126b2）在维持性血液透析患者中的细胞免疫原性和体液免疫原性。
EBioMedicine. 2021 Sep;71:103567. doi: 10.1016/j.ebiom.2021.103567. Epub 2021 Aug 26.
10
COVID-19 Vaccines Based on Adenovirus Vectors.基于腺病毒载体的新冠病毒疫苗
Trends Biochem Sci. 2021 May;46(5):429-430. doi: 10.1016/j.tibs.2021.03.002. Epub 2021 Mar 14.
引用本文的文献
1
Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status.血清蛋白质组学特征与希腊接受过 SARS-CoV-2 疫苗接种的医护人员的既往感染状况相关。
Int J Mol Sci. 2022 Sep 5;23(17):10153. doi: 10.3390/ijms231710153.
2
Exploring COVID-19 pathogenesis on command-line: A bioinformatics pipeline for handling and integrating omics data.探索命令行上的 COVID-19 发病机制：用于处理和整合组学数据的生物信息学管道。
Adv Protein Chem Struct Biol. 2022;131:311-339. doi: 10.1016/bs.apcsb.2022.04.002. Epub 2022 May 12.
3
Host cell proteins modulated upon Toxoplasma infection identified using proteomic approaches: a molecular rationale.利用蛋白质组学方法鉴定弓形虫感染后调节的宿主细胞蛋白：分子原理。
Parasitol Res. 2022 Jul;121(7):1853-1865. doi: 10.1007/s00436-022-07541-4. Epub 2022 May 13.
本文引用的文献
1
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.与原始 SARS-CoV-2 株相比，感染 B.1.1.7 后抗体交叉反应性降低。
Elife. 2021 Jul 29;10:e69317. doi: 10.7554/eLife.69317.
2
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
3
Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19.免疫系统蛋白质相互作用组网络分析、人体组织单细胞RNA测序及人工神经网络揭示了新冠病毒药物再利用的潜在治疗靶点。
Front Pharmacol. 2021 Feb 26;12:598925. doi: 10.3389/fphar.2021.598925. eCollection 2021.
4
Emergence of a Novel SARS-CoV-2 Variant in Southern California.新型 SARS-CoV-2 变异株在南加州出现。
JAMA. 2021 Apr 6;325(13):1324-1326. doi: 10.1001/jama.2021.1612.
5
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.瑞德西韦（EIDD-2801）能有效治疗和预防 SARS-CoV-2 感染。
Nature. 2021 Mar;591(7850):451-457. doi: 10.1038/s41586-021-03312-w. Epub 2021 Feb 9.
6
An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.基于深度学习的多表位疫苗设计：以 SARS-CoV-2 为例的研究。
Sci Rep. 2021 Feb 5;11(1):3238. doi: 10.1038/s41598-021-81749-9.
7
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.鉴定导致 SARS-CoV-2 刺突突变的单克隆和血清抗体中和作用减弱的抗体。
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4. doi: 10.1016/j.chom.2021.01.014. Epub 2021 Jan 27.
8
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant.新冠病毒：诺瓦瓦克斯疫苗对英国变种的效力为86%，对南非变种的效力为60%。
BMJ. 2021 Feb 1;372:n296. doi: 10.1136/bmj.n296.
9
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.结构导向的多价纳米抗体可阻断 SARS-CoV-2 感染并抑制突变逃逸。
Science. 2021 Feb 12;371(6530). doi: 10.1126/science.abe6230. Epub 2021 Jan 12.
10
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).多方面、高针对性、序贯、多药物早期门诊高危 SARS-CoV-2 感染（COVID-19）治疗。
Rev Cardiovasc Med. 2020 Dec 30;21(4):517-530. doi: 10.31083/j.rcm.2020.04.264.
Zotero 插件